1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Guardant Health's 1-Year ROIIC % for the quarter that ended in Mar. 2024 was 97.41%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Guardant Health's 1-Year ROIIC % or its related term are showing as below:
GH's 1-Year ROIIC % is ranked better than 82.46% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.11
vs GH: 97.41
Guardant Health 1-Year ROIIC % Historical Data
The historical data trend for Guardant Health's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Guardant Health's 1-Year ROIIC %
For the Diagnostics & Research subindustry, Guardant Health's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health's 1-Year ROIIC % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Guardant Health's 1-Year ROIIC % falls into.
Guardant Health 1-Year ROIIC % Calculation
Guardant Health's 1-Year ROIIC % for the quarter that ended in Mar. 2024 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -531.6017 (Mar. 2024) - -556.3134 (Mar. 2023) )
/
( 539.204 (Mar. 2024) - 513.834 (Mar. 2023) )
=
24.7117
/
25.37
=
97.41%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Guardant Health (NAS:GH) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Guardant Health 1-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Guardant Health's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Guardant Health (Guardant Health) Business Description
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GH has been successfully added to your 